Browse Articles

Discover research articles across all indexed journals

Health related quality of life (HRQOL) and early clinical outcomes of high - very high risk prostate cancer treated with linac based stereotactic body radiotherapy (SBRT) and long term androgen deprivation therapy (ADT).

Journal of Clinical Oncology Jay Prakash Sahu, Trinanjan Basu, Komal Jaikishan Parwani et al. Jul 01, 2026 DOI: 10.1200/jco.2026.44.19_suppl.191

191 Background: Stereotactic body radiotherapy (SBRT) in NCCN high-risk (HR) and very high-risk (VHR) prostate cancer is evolving but limited by long-term oncologic outcome and quality of life (QOL) data. We report early clinical outcomes in terms of biochemical disease-free rate, overall survival (OS) rate, health related QOL (HRQOL) and toxicity in HR and VHR prostate cancer treated by Linac based SBRT and long term androgen deprivation therapy (ADT). Methods: NCCN HR and VHR, treated with uniform protocol of Linac based SBRT (prostate and pelvic nodes - 36.25Gy/25Gy/5 fractions/alternate days) with long term ADT (18-24 months) were included. HRQOL was assessed for urinary incontinence, urinary obstructive, bowel, sexual and hormonal domains by Expanded Prostate Cancer Index Composite for Clinical Practice (EPIC‐CP) questionnaire. Maximum score of 12 for each domain, lower score indicating better HRQOL. EPIC-CP was documented pre SBRT, 6 monthly till 24 months and at 36 months post SBRT. Acute and late genitourinary (GU) and gastrointestinal (GI) adverse events were recorded as per RTOG. Survival curves were calculated by Kaplan-Meier curve. Results: 70 patients were analyzed. Median age was 71 years, majority (55.7%) had moderate pre SBRT International Prostate Symptom Score (IPSS). The median baseline serum PSA was 25.44. HR and VHR category 39 (55.7%) and 31 (44.3%) respectively. Median follow-up (FU) was 21 months, five patients lost to FU and nine died of non-prostate cancer related causes. Three patients had biochemical recurrence and one had metastatic progression. At 3 year biochemical disease-free rate, OS rate was 91% and 81% respectively. The median OS was 26 months. Acute grade 2 GU and GI adverse events were reported in 14 (20%) and 8 (11.4%) respectively. Late grade 3 GI/GU adverse events in one patient each. Pre-SBRT mean HRQOL scores were 1.2 (urinary incontinence), 1.3 (urinary obstructive), 0.3 (bowel), 5.6 (sexual) and 0.78 (hormonal). At 24 months mean urinary incontinence and obstructive scores decreased to 0.68 and 0.72 respectively, indicating probable recovery, while bowel score remained stable at 0.28. Till 24 months mean sexual (7.6) and hormonal (2.19) scores showed increasing trend indicating worsening of QOL followed by a decline at 36 months (6.2 and 1.2 respectively) representing probable recovery. Mean EPIC CP score pre SBRT and at 24 months was statistically significant for sexual domain (p=0.01 by paired t-test). Conclusions: Linac based SBRT with long term ADT achieved encouraging biochemical control and fewer adverse events with favourable urinary and bowel HRQOL in HR and VHR prostate cancer. Overall survival did not emerge significantly owing to shorter follow-up. We are in the process of prospective documentation of long-term outcomes and adverse events.

Adebrelimab plus interventional and targeted therapy for unresectable hepatocellular carcinoma: A single-arm, real-world study.

Journal of Clinical Oncology Chenchen Zhao, Dongmei Quan, Jiye Song et al. Jul 01, 2026 DOI: 10.1200/jco.2026.44.19_suppl.107

107 Background: Systemic therapy with immune checkpoint inhibitors (ICIs) and targeted agents, in combination with interventional therapy, has become a standard treatment strategy for advanced hepatocellular carcinoma (HCC). However, clinical evidence for PD-L1 inhibitor–based combination regimens in HCC remains limited, particularly in real-world settings. This study reports preliminary real-world outcomes of adebrelimab (a PD-L1 inhibitor) combined with targeted therapy and interventional treatment in patients with unresectable HCC. Methods: Patients with treatment-naïve unresectable HCC (CNLC Ib–IIIb; Child–Pugh A/B; ECOG PS 0–2) were enrolled. All patients received adebrelimab (1200 mg, IV, Q3W) in combination with targeted agents and interventional therapy. Interventional therapy, including transarterial chemoembolization (TACE), hepatic arterial infusion chemotherapy (HAIC), or other procedures, was selected by investigators according to tumor burden and clinical status. Targeted agents included, but were not limited to, monoclonal antibodies such as bevacizumab and small-molecule targeted therapies (TKIs) such as lenvatinib. The primary endpoint was objective response rate (ORR). The secondary endpoints were progression-free survival (PFS), disease control rate (DCR), overall survival (OS), and safety. Results: As of January 2026, 13 patients were enrolled. The median age was 57 years (range, 48–74), and 85% were male. Most patients had advanced disease (CNLC IIIA, 77%), Child–Pugh class A/B liver function (38%/62%), and high tumor burden (77% beyond up-to-7). Chronic viral hepatitis (HBV or HCV) was present in 85% of patients, reflecting real-world HCC characteristics in China. Regarding interventional therapy, 9 patients (70%) received TACE, 3 (23%) received HAIC, and 1 underwent ablation. For targeted therapy, 7 patients (54%) received bevacizumab and 6 (46%) received lenvatinib. The median treatment duration was 4.7 months (range, 0.7–13.4). Among 13 patients evaluable for response, 3 achieved partial response, 8 had stable disease, and 2 had progressive disease, yielding an ORR of 23.1% and a DCR of 84.6%. Median PFS and OS were not reached at the time of analysis. Grade ≥3 treatment-related adverse events occurred in 5 patients, mainly neutropenia, leukopenia, and thrombocytopenia. Conclusions: In a real-world setting, adebrelimab (PD-L1)–based immune–targeted systemic therapy plus interventional treatment showed encouraging antitumor activity with manageable toxicity in patients with unresectable HCC. Clinical trial information: ChiCTR2400091083 .

Iron-Catalyzed Chemodivergent Sequential Reactions of Alkynes and Organozinc Reagents

Journal of the American Chemical Society Tao Cai, Peng He, Shen-Ao Xie et al. Jul 01, 2026 DOI: 10.1021/jacs.6c05428

Synergistic CuO-CeO2 nanocomposites with narrow band gap for high-performance photocatalysis under solar light irradiation and antibacterial action

Scientific Reports A. Antony Arokya Sangeetha Devi, D. Vasvini Mary, K. Yesuraj et al. Jul 01, 2026 DOI: 10.1038/s41598-026-54689-5

N4-Acetylcytidine enhances synthetic mRNA translation yield and fidelity

Nature Sarah Schiffers, Blake W. Nelson, Maria Prigge et al. Jul 01, 2026 DOI: 10.1038/s41586-026-10729-8

Abstract Synthetic mRNA therapeutics offer a versatile platform for treating diverse conditions, including cancer and infectious diseases. For delivery into cells, these mRNAs are encapsulated in lipid nanoparticles and commonly incorporate modified ribonucleotides to improve stability, enhance translation and mitigate immune recognition 1 . N 1 -Methylpseudouridine (m 1 Ψ) has become the industry standard for synthetic mRNAs owing to its effectiveness in promoting translation and reducing immunogenicity 2 . However, recent studies have shown that m 1 Ψ can compromise translational fidelity, leading to errors such as premature termination and ribosomal frameshifting 3–5 . Here we reveal N 4 -acetylcytidine (ac 4 C) as a functionally distinct alternative to m 1 Ψ. Across cultured cell lines, primary human monocyte-derived dendritic cells and mouse liver, ac 4 C suppressed inflammatory responses as effectively as m 1 Ψ while driving higher protein yields. Single-molecule imaging of translation revealed broadly similar ribosome densities per mRNA for ac 4 C-modified and m 1 Ψ-modified transcripts. However, translation elongation with m 1 Ψ-modified mRNA was nearly twofold slower than with ac 4 C, which resulted in reduced protein output and increased ribosome collisions that further limited protein production through the engagement of quality-control pathways and +1 frameshifting. These findings underscore the importance of context in designing therapeutic mRNAs and position the translation elongation rate as a key determinant of the efficacy of modified ribonucleotides.

Active‐Metal‐Rich Intermetallics as a Platform for Tiered Interstitial Electronic States

Advanced Materials Yijia Liu, Yi Lin, Zhilin Guo et al. Jul 01, 2026 DOI: 10.1002/adma.73783

ABSTRACT Interstitial electronic states, commonly found in F‐centers and electrides, have garnered significant attention in materials discovery, and applications spanning catalysis and electronics. Here, we demonstrate that active‐metal‐rich intermetallics serve as a platform for forming diverse cationic cages that accommodate distinct interstitial electrons. This arises from two key factors: (1) the high atomic density of active metals, promoting their aggregation to form cages; and (2) the high valence electron density, facilitating electron confinement in cage voids. We examine 10 metal‐rich RE–T–Al/Mg (RE = rare earth, T = transition metal) ternary compounds as examples. Density functional theory (DFT) calculations reveal that these compounds exhibit electride characteristics, featuring tiered interstitial electrons at distinct Wyckoff sites and energy levels. Detailed analyses identify two types of interstitial electrons: those in RE‐rich cages, with band centers at −1.25 eV< E − E F < 0 eV, ∼1 e − /site, and negative hydrogen binding energies, exhibiting anionic‐like behavior; and those in Al cages, with band centers at E − E F < −1.8 eV, ∼2 e − /site, and positive hydrogen binding energies, displaying covalent‐like behavior. Our results provide a systematic insight into interstitial electrons in RE–T–Al/Mg ternary compounds, potentially offering a guideline for designing intermetallic compounds with tailored interstitial electronic states.

Impedance‐Domain Decoupled Single‐Architecture Multimodal Strain Sensor Array for Full‐Field Strain Mapping

Advanced Materials Hao Yin, Tao Wang, Wangze Ni et al. Jul 01, 2026 DOI: 10.1002/adma.73557

ABSTRACT Multimodal strain sensors integrating diverse transduction mechanisms expand sensing dimensionality. However, most multimodal devices rely on complex integrated architectures to suppress crosstalk and lack intrinsic sensing pathways for capturing strain dynamics. Here, we present a highly simplified multimodal sensor based on a single sandwich‐type piezoelectric architecture, where a microcrack‐based piezoresistive layer simultaneously serves as the piezoelectric electrode, enabling intrinsically decoupled sensing within a shared electrical channel via impedance‐domain separation. Notably, the piezoelectric output directly reflects strain rate, complementing the piezoresistive readout of strain magnitude to achieve integrated dynamic–static strain sensing. Scalable and low‐cost ultrasonic spray coating is further developed to fabricate large‐area arrays (>10 cm × 10 cm) with uniform morphology and reliable performance. Owing to PVP‐regulated ink composition, the piezoresistive layer exhibits an ultrawide linear strain range of 0.001%–45% and a dynamic response up to 700 Hz. Integrated with multichannel acquisition electronics, the platform enables spatiotemporal mapping of micron‐scale deformations and strain trajectories, facilitating more reliable identification of failure sites under vibrational excitations and establishing a robust framework for comprehensive, high‐fidelity structural health assessment.

Localized Temperature Monitoring in Mouse Brain during Light Delivery via a Non‐Planar Tapered Fiber‐Integrated µRTD Sensor

Advanced Materials Antonio Balena, Marco Bianco, Barbara Spagnolo et al. Jul 01, 2026 DOI: 10.1002/adma.202519655

ABSTRACT Monitoring local brain temperature with high spatial precision is essential to understanding neurophysiological processes and managing the side effects of optical neuromodulation techniques. We present a novel multifunctional neural interface integrating a microscale resistance temperature detector (µRTD) onto the curved surface of a tapered optical fiber (TF), enabling co‐localized light delivery and thermal sensing with minimal footprint. The µRTD, patterned via an unconventional two‐photon polymerization (TPP)‐based process on the fiber surface, exhibits thermal sensitivity <0.1°C and low self‐heating under physiologically‐safe bias conditions. We demonstrate the system's capacity to resolve subtle temperature changes induced by optogenetic stimulation/inhibition protocols (the latter requiring illumination periods of hundreds of milliseconds up to several seconds), revealing significant thermal accumulation only under long, high‐intensity illumination. This integration resolves the spatial mismatch of multimodal probes and reduces implant cross‐section compared to coaxial or side‐by‐side configurations. Furthermore, the TPP approach is modular, allowing integration with additional functionalities (i.e., electrophysiological recording or thermoplasmonics). By uniting photonic and thermal readout into a minimally invasive probe, our technology offers a powerful tool for studying thermally mediated neural processes, enhancing the safety and interpretability of optical neurotechnologies. Its integration potential positions this platform as a complementary technology for next‐generation multifunctional neural interfaces.

Neoadjuvant toripalimab combined with TIP chemotherapy for locally advanced penile squamous cell carcinoma: A multicenter prospective, single-arm, phase II clinical trial.

Journal of Clinical Oncology Ting Xue, Longbin Xiong, Qing Yang et al. Jul 01, 2026 DOI: 10.1200/jco.2026.44.19_suppl.178

178 Background: The neoadjuvant regimen of paclitaxel, ifosfamide, and platinum (TIP) regimen is recommended for local advanced penile squamous cell carcinoma (La-PSCC) by NCCN guideline; however, its objective response rate (ORR) is only 50%, with limited long-term survival benefits. This phase II study was designed to evaluate the efficacy and safety of toripalimab (anti-PD-1 monoclonal antibody) combined with TIP chemotherapy as neoadjuvant therapy in chemotherapy-naïve patients with La-PSCC. Methods: This was a prospective, multicenter, single-arm phase II study utilizing a Simon’s two-stage design. Patients with T4 or N2-3 M0 PSCC received up to four cycles of neoadjuvant toripalimab combined with TIP chemotherapy, followed by consolidative surgery. Postoperatively, toripalimab maintenance therapy was administered every three weeks for up to 17 cycles. The primary endpoint was the ORR assessed according to RECIST v1.1. Secondary endpoints include pathological complete response (pCR), event-free survival (EFS), overall survival (OS), and the incidence of treatment-related adverse events (TRAEs). This trial is registered on ClinicalTrials.gov (Identifier: NCT06415318). Results: From May 30, 2024, to Jun 1, 2025, a total of 25 patients with La-PSCC were enrolled (median age 60 years, range 31-71). All received ≥2 cycles of toripalimab combined with TIP chemotherapy. The ORR was 84.0% (21/25), with 2 patients (8.0%) achieving CR and 19 (76.0%) achieving PR. Twenty-one patients received following consolidative surgery, with a pCR rate of 48.0% (12/25). All patients (100%) experienced TRAE of any grade; grade 3-4 TRAEs occurred in 84.0% (21/25). The most common grade 1-2 TRAEs were alopecia (100%), peripheral neuropathy (96.0%), and fatigue (84.0%). The predominant grade 3–4 TRAEs were neutropenia (72.0%, 18/25) and leukopenia (60.0%, 15/25). Hypothyroidism (grade 1–2) was the main immune-related adverse event (irAE), affecting 2/25 patients (8%). No grade 5 TRAEs or treatment-related deaths occurred. At a median follow-up of 14.8 months, the 12-month EFS and OS rates were 71.6% (95% CI: 55.8–91.9) and 87.8% (95% CI: 75.8–100), respectively. Median EFS and OS were not reached. Mature survival data are awaited with longer follow-up. Conclusions: Neoadjuvant toripalimab combined with TIP chemotherapy exhibits significant efficacy in chemotherapy-naïve patients with La-PSCC, with acceptable treatment-related toxicity. This combination holds great promise as a new standard neoadjuvant treatment for La-PSCC. Clinical trial information: NCT06415318 .

Adebrelimab plus apatinib for maintenance treatment of extensive-stage small cell lung cancer after first-line induction with adebrelimab plus chemotherapy (CLOG2402-ADAPT): A multi-center, single-arm, phase II trial.

Journal of Clinical Oncology Lingyun Zhang, Xiuna Zhang, Jinhua Piao et al. Jul 01, 2026 DOI: 10.1200/jco.2026.44.19_suppl.271

271 Background: Immune checkpoint inhibitors (PD-1/PD-L1) combined with chemotherapy have become the standard first-line treatment for ES-SCLC, but long-term benefit remains limited. Anti-angiogenic therapy with immunotherapy has shown promising activity and may offer synergistic antitumor effects. This study reports the preliminary results of the CLOG2402-ADAPT trial evaluating adebrelimab (a PD-L1 inhibitor) plus apatinib (a VEGFR-2 tyrosine kinase inhibitor) as maintenance therapy. Methods: Patients with ES-SCLC who had not progressed after 4–6 cycles of 1L induction therapy with adebrelimab plus platinum–etoposide were eligible to enter the maintenance phase. These patients received maintenance adebrelimab(1200 mg, IV, q3w) plus apatinib (250 mg, po, qd) until progression, toxicity, or withdrawal. The primary endpoint was progression-free survival (PFS), defined as the time from initiation of maintenance therapy to the first documented disease progression. Secondary endpoints included overall survival (OS), objective response rate (ORR), disease control rate (DCR), time to second progression (PFS2). Results: As of February, 2026, 19 patients entered maintenance phase with a median follow-up of 7.4 months (range 3.4–15.6). Median age was 65 years (49–77); Male and female patients accounted for 58% and 42%. 58% had a current or previous smoking history. Liver metastases were present in 16% and brain metastases in 20%. The median duration of induction therapy was 4.0 months (range, 2.3–6.2). Most patients (85%) achieved a partial response to induction therapy. During the maintenance phase, 17 patients underwent at least one tumor response assessment. The ORR was 12%, with a DCR of 71% (comprising 2 PR, 10 SD, and 2 PD). Median PFS was 4.37 months during the maintenance phase, while the the median PFS from the first dose was 8.43 months. OS remain immature. Treatment-related adverse events (TRAEs) occurred in 86.7% of patients, with grade 3 TRAEs in 13.3% (elevated lipase; interstitial pneumonitis). No treatment-related deaths occurred. Conclusions: Adebrelimab plus apatinib showed clinically meaningful antitumor activity and acceptable tolerability as 1L maintenance therapy in patients with ES-SCLC following induction with adebrelimab plus chemotherapy. Clinical trial information: NCT06480864 .

Chemoenzymatic Synthesis of Asymmetric <i>N</i> -Glycans in Aqueous Solution via Sulfate and Phosphate Orthogonal Protection

Journal of the American Chemical Society Pengxi Chen, Ruofan Li, Yi-Fang Zeng et al. Jul 01, 2026 DOI: 10.1021/jacs.6c06320

Excited‐State Pathway Switching via Reversible Structural Phase Transitions in Sb <sup>3+</sup> ‐Doped Cadmium Halides

Angewandte Chemie International Edition Zhe Tang, Binbin Fan, Chenxin Fan et al. Jul 01, 2026 DOI: 10.1002/anie.9627340

ABSTRACT Reversible control of structural phase transitions and luminescence remains a key challenge in organic–inorganic hybrid metal halides for stimuli‐responsive photonic applications. Here, we report two new zero‐dimensional (0D) Cd‐based metal halides, (DFPD) 6 CdCl 8 and (DFPD) 2 CdCl 4 ·H 2 O (DFPD + = 4,4‐difluoropiperidine), in which Sb 3+ doping enables distinct emission behaviors governed by coordination geometry. Combined spectroscopic studies and theoretical calculations reveal that Sb 3+ ‐doped (DFPD) 6 CdCl 8 exhibits yellow emission with a large Stokes shift arising from triplet self‐trapped exciton ( 3 STE) emission, whereas Sb 3+ ‐doped (DFPD) 2 CdCl 4 ·H 2 O displays excitation‐dependent emission due to competing singlet STE ( 1 STE) and 3 STE states. This contrast originates from the different Cd–Cl coordination environments (octahedral vs. tetrahedral), which modulate the energy levels and transition dipole moments. Importantly, hydrochloric acid (HCl) and 4,4‐difluoropiperidine induce fully reversible interconversion between the two structures, allowing dynamic switching between yellow and deep‐orange emission. Based on this reversible luminescence, we further demonstrated applications in dynamic anti‐counterfeiting and multilevel information encryption. This work establishes a coordination‐structure‐driven strategy for programmable emission in 0D hybrid metal halides.

An interpretable AI framework using XGB-POA for micropile compressive stiffness prediction

Scientific Reports Mohammadreza Ahmadi Golsefidi, Mahzad Esmaeili-Falak, Hossein Sarbaz Jul 01, 2026 DOI: 10.1038/s41598-026-60145-1

Steatosis shapes prognosis-defining liver metastasis heterogeneity in CRC

Nature Yiming Peng-Winkler, Xiao-Zheng Liu, Sanne M. L. Verheul et al. Jul 01, 2026 DOI: 10.1038/s41586-026-10686-2

Amphiphilic Bonding Intercalation Reshapes Active Sites and Interlayer Microenvironment for Selective and Stable Seawater Oxidation

Advanced Materials Feng Dong, Changqing Lin, Jinqiang Gao et al. Jul 01, 2026 DOI: 10.1002/adma.73812

ABSTRACT Direct seawater electrolysis is severely constrained by the activity‐durability trade‐off and chloride‐induced corrosion. Herein, we design corrosion‐resistant, highly selective layered double hydroxide (LDH) catalysts by transitioning interlayer bonding from weak electrostatic attraction to strong coordination. Amphiphilic dodecylbenzenesulfonate (SDBS) coordinates with Fe active centers, forming robust Fe─O─S bonds that establish a securely locked microenvironment. Density functional theory reveals this coordination upshifts the Fe d‐band center and enhances Fe─O covalency, lowering the thermodynamic oxygen evolution barrier. Simultaneously, molecular dynamics simulations show that hydrophobic alkyl tails reorganize the interfacial hydrogen‐bond network. This creates a kinetic barrier against chloride, enabling high hydroxide‐to‐chloride diffusion selectivity (D OH − /D Cl − ≈ 1.94). Consequently, the NiFe‐SDBS electrode decouples stability from activity, delivering an ultralow overpotential of 239 mV at 10 mA cm −2 and sustaining 1000 mA cm −2 for &gt;1000 h with negligible degradation. In a zero‐gap anion exchange membrane (AEM) electrolyzer, it achieves 1000 mA cm −2 at ∼4.64 kWh Nm −3 and maintains robust stability (&gt;600 h at 500 mA cm −2 ) with an ultra‐low degradation rate of 0.18 mV h −1 . This work establishes coordination‐driven microenvironment engineering as a generalizable paradigm for durable electrocatalyst design.

A Visual Inertia‐Inspired Multimode Sensor Based on Pb–S Strongly Coupled Heterostructures for Information Fusion Positioning and Monitoring

Advanced Materials Leping Li, Chenhao Xu, Lei Zheng et al. Jul 01, 2026 DOI: 10.1002/adma.73515

ABSTRACT The visual‐inertial odometry (VIO) system enables continuous and accurate tracking of high‐speed moving objects, offering distinct advantages for unmanned vehicles and mobile robots, but spatiotemporal inconsistency between components data often degrades overall performance. Here, we demonstrate a visual inertia‐inspired multimode sensor (VIMS) based on FAPbI 3 (FA/PbI 2 = 4:1) organic–inorganic hybrid perovskite quantum dots (OIHPQDs) sensitized MoS 2 heterostructure, featuring reconfigurable photodetector (PD) and photosynaptic (PS) functions, successfully demonstrating single‐device functional integration for VIO. The heterostructure exhibits light‐power‐selective, Pb–S coupled‐mediated charge transport, enabling distinct light response speeds for PD and PS mode switching while overcoming the need for lattice matching in heterostructure coupling. Moreover, uniform‐sized FAPbI 3 is obtained using a self‐designed microfluidic technique, ensuring excellent reproducibility in the fabricated heterointerface. The developed devices exhibit a high specific detectivity ( D * ) gain of ≈ 1000 under 0.039 mW/cm 2 dim light, excellent synaptic plasticity with 90% recognition accuracy and 40% noise tolerance, and optical secure communication capability with response times over 10 times faster than in PS mode. More importantly, the dual‐mode VIMS array enables real‐time tracking of dynamic grayscale and static attitude information from high‐speed Newton's cradle and billiards, demonstrating dynamic/static information fusion for positioning and monitoring.

Implementation of a patient-reported symptom tool in low-resource settings with high demand for services: A pilot feasibility study (PROMISE-Pilot).

Journal of Clinical Oncology Jayson L. Co, Kevin Lee Min Chua, Durgesh Innani et al. Jul 01, 2026 DOI: 10.1200/jco.2026.44.19_suppl.352

352 Background: Patients often experience cancer and treatment-related symptoms that can be under-elicited and under-reported especially in busy oncology clinics and not be prioritised appropriately. This is especially true in Asia with widespread resources and workforce constraints. Systematic symptom monitoring using patient reported outcome measures tools (PROMs) has been shown to improve outcomes in the West, but feasibility and acceptability in Asian contexts remain uncertain. Four oncology services in Thailand, India, Singapore and the Philippines evaluated the feasibility of implementing PROMs in routine outpatient oncology care. Methods: PROMiSE was a prospective, multi-center feasibility study evaluating integration of PROMs using Edmonton Symptom Assessment Scale-revised (ESAS-r) into outpatient oncology practice in Asia. Clinicians at four hospitals in Singapore, Manila, Bangkok, and Hyderabad participated, with participating patients completing paper-based ESAS-r prior to each clinic visit. The primary endpoint was completion of ESAS-r, defined as ≥85% of patients completing ≥5 of 10 ESAS-r items. Secondary endpoints included completion of ≥8 and all 10 items, patient- and clinician-reported satisfaction using study-developed surveys. Results: A total of 819 patients answered the ESAS-r with 817 (99.8%) completing ≥5 items and 811 (99.0%) completing ≥8 items. Majority were ECOG performance status ≤2 (728; 93.9%).The majority of ESAS-r forms were answered by the patients (524; 67.6%), while the remainder required caregiver assistance. Patient-reported feedback (1 = strongly agree, 5 = strongly disagree) demonstrated high acceptability: ESAS-r was easy to answer (mean 1.34±0.60), easy to understand (1.34±0.58), relevant to them (1.41±0.64), improved discussion with clinicians (1.49±0.72), was used by their clinicians (1.58±0.81), increased their sense of control (1.55±0.74), and they will recommended to others (1.55±0.75). Most clinicians agreed that ESAS-r improved quality of care, consultation efficiency, and clinical discussions, and reported intent for future use. Conclusions: The study demonstrates feasibility and patient and clinician acceptability of ESAS-r, a low-cost but potentially high-value tool that can improve quality of care, across different sites in Asia. The high completion rates, positive patient and clinician feedback indicate that ESAS-r can be considered for a wider scale adoption in routine outpatient oncology clinics in Asia. However, local institutional, guideline and policy level changes will be required to enable sustainable uptake and implementation of PROMs into practice.

Strengthening nurse-led clinical breast examination (CBE) screening through quality improvement: A prospective implementation study from a tertiary hospital in eastern India.

Journal of Clinical Oncology Dr. Kahkasha, Rakhi Gaur Jul 01, 2026 DOI: 10.1200/jco.2026.44.19_suppl.315

315 Background: India, representing nearly one-fifth of the global female population, faces a rapidly increasing breast cancer burden. The age-adjusted incidence rate has risen from 25 per 100,000 in the 1990s to nearly 40 per 100,000 in 2022. Alarmingly, over 60% of Indian women are diagnosed in locally advanced or metastatic stages. While the National Program for Prevention and Control of Cancer, Diabetes, Cardiovascular Diseases and Stroke (NPCDCS) provides a policy framework for screening, its operationalization remains limited by workforce and infrastructure constraints. Nurse-led CBE models, integrated into existing hospital workflows, have the potential to address these gaps efficiently. At our institution, women attending the General Surgery OPD were not routinely offered CBE unless they presented with breast complaints. Nurses, though integral to patient flow, were minimally involved in cancer screening and rarely engaged in Quality Improvement (QI) efforts. This presented an opportunity to transform existing human resources into active participants in cancer prevention. Methods: A prospective Quality Improvement study was conducted at a tertiary care teaching hospital in eastern India. The project adopted the Model for Improvement, focusing on iterative PDSA cycles. A multidisciplinary QI team did a Gemba walk of the General Surgery OPD to observe the workflow and identify barriers to screening. The fishbone diagram and Pareto chart identified major obstacles. Four sequential PDSA cycles were implemented, each lasting approximately one month namely hands-on nurse training, developing Institutional policies, empowering nurses to conduct CBE independently and institutionalizing recurrent training to address nurse rotation and attrition. Results: The baseline CBE rate in August 2024 was 0%. After the first intervention cycle, the screening rate rose to 36%. Following further workflow optimization and patient engagement, the rate stabilized above 60%, reaching 63.6% at six months. Among those screened, the ones showing abnormalities such as palpable lumps, skin dimpling, or nipple discharge were referred to surgical oncologists for further diagnostic evaluation. Nurses reported enhanced confidence and professional ownership. The administrative leadership noted improved patient satisfaction and expressed willingness to scale the model across departments. Conclusions: Nurse-led CBE screening implemented through structured QI methodology significantly improved screening uptake and awareness among women in a tertiary care hospital in eastern India. This initiative demonstrated that task-shifting to trained nurses is feasible, scalable, and sustainable within LMIC health systems.

Pressure-Induced Superconductivity in the Thermoelectric Semiconductor Mg <sub>3</sub> Sb <sub>2</sub>

Journal of the American Chemical Society Cuiying Pei, Yasong Wu, Airan Li et al. Jul 01, 2026 DOI: 10.1021/jacs.6c06354

Genome-wide identification and expression analysis of NAC transcription factors in Pterocarpus santalinus: identification of candidate genes associated with leaf senescence

Scientific Reports Xianglong Wang, Yingbing Hu, Hongfei Lu et al. Jul 01, 2026 DOI: 10.1038/s41598-026-60653-0